Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross‐sectional observational study. (20th February 2022)

• Record Type: Journal Article
• Authors: Lee, Sang‐Hoon; Kim, Yong‐Gil; Lee, Seung‐Geun; Lee, Soo Hyun; Kim, Young‐Joo; Jeon, Ja‐Young; Jo, Joo‐Young; Yoo, Hyun‐Jeong; Lee, Juneyoung; Kim, Tae‐Hwan
• Is Part Of: International journal of rheumatic diseases. Volume 25:Number 5(2022)
• Page Start: 523
• Page End: 531
• Publication Date: 2022-02-20
• Subjects: ankylosing spondylitis -- patient satisfaction -- productivity loss -- treatment pattern -- tumor necrosis factor inhibitor; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.14304
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Aim: To provide in‐depth understanding of real‐world tumor necrosis factor inhibitor (TNFi) treatment patterns in patients with ankylosing spondylitis (AS) and treatment satisfaction, productivity loss, and associated factors. Methods: This was a multicenter observational hybrid retrospective chart review and cross‐sectional survey study. Disease activity and physical functioning were measured using the Bath AS Disease Activity Index and Bath AS Functional Index, respectively. Treatment satisfaction was determined with the Treatment Satisfaction Questionnaire for Medication (TSQM). Productivity loss was evaluated using the Korean version of the World Health Organization–Health and Work Performance Questionnaire. Results: A total of 497 patients were enrolled (mean age 40.3 years, 85.3% male, mean AS duration 10 years). The mean duration of TNFi treatment was 6.2 years. Among the four TNFi considered, adalimumab (39.6%) and etanercept (23.5%) were most commonly used at study enrollment. The TSQM convenience domain score was lower than scores in the effectiveness, adverse effects, and global satisfaction domains. Subcutaneous syringe‐type injection and intravenous injection were associated with lower patient convenience satisfaction than subcutaneous pen‐type injection. Increased costs of lost productivity time were associated with female sex, unemployed status, and higher disease activity. Conclusions: The most frequently prescribed TNFi was adalimumab, followed by etanercept. Etanercept was used for the longest duration. More convenient treatment options may enhance overall treatment satisfaction. Considerable loss in productivity due to AS was observed in this study. To reflect patients' perspectives, further attention should be paid to factors associated with treatment satisfaction and productivity loss when selecting treatment options.